- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.11.25 | Merus and Halozyme link on subcutaneous petosemtamab | ||
| 18.11.25 | Johnson & Johnson to acquire Halda Therapeutics for $3.05bn | ||
| 17.11.25 | Henlius and Organon score first US Perjeta biosimilar approval | ||
| 17.11.25 | High-dose Spinraza inches closer to EU approval despite FDA setback | ||
| 17.11.25 | Medicxi unveils €500m fund for asset-centric biotechs | ||
| 17.11.25 | FDA approves Sarepta's updated Elevidys label for DMD | ||
| 17.11.25 | Sofinnova closes €650m healthcare fund for early-stage ventures | ||
| 14.11.25 | MSD bets big on flu antivirals with $9.2bn buyout of Cidara | ||
| 14.11.25 | Eli Lilly and Novo Nordisk disown Mangoceuticals' GLP-1RA partnership claim | ||
| 14.11.25 | Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy | ||
| 14.11.25 | General Proximity and Daiichi Sankyo link on oncology | ||
| 14.11.25 | Eisai and Biogen report Leqembi's MHRA approval for Alzheimer's | ||
| 13.11.25 | Metagenomi culls 25% of its workforce and replaces CEO in reshuffle | ||
| 13.11.25 | FDA unveils new pathway to usher bespoke therapies to market | ||
| 13.11.25 | EuropaBio calls for "bold approach to investment" amid EU Biotech Act | ||
| 13.11.25 | CPHI 2025: 'handprint' metric bridges pharma sustainability and economic value | ||
| 13.11.25 | Chiesi and Aliada sign licence deal for enzyme replacement therapies | ||
| 13.11.25 | BostonGene and Kyoto University link on oesophageal cancer drug | ||
| 12.11.25 | Sandoz CEO forecasts a Q1 or Q2 market entry for semaglutide biosimilars in Canada | ||
| 12.11.25 | Modulight secures $12m to shine precise light on neurological diseases | ||
| 12.11.25 | FDA's revolving door reveals Pazdur as new CDER head | ||
| 12.11.25 | Dyno Therapeutics and Trisk Bio partner for strategic manufacture | ||
| 12.11.25 | March Bio's MB-105 gains FDA RMAT for CD5+ T-cell lymphoma | ||
| 11.11.25 | FDA calls for black box warning to be removed from HRT products | ||
| 11.11.25 | Lyell acquires worldwide rights from ICT to CAR T-cell therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .